References
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10(5):589–95.
- Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil 2010;24(4):293–304.
- Sosnoff JJ, Gappmaier E, Frame A, Motl RW. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J Neurol Phys Ther 2011;35(3):129–32.
- Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair 2003;17(1):66–70.
- de Sa JC, Airas L, Bartholome E, Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011;4(3):139–68.
- Oreja-Guevara C. Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. Rev Neurol 2012;55(7):421–30.
- Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009;26(12):1043–57.
- Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97(10):671–6.
- Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. J Neurosci Nurs 2008;40(1):25–31.
- Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, et al; for Spanish Group on Spasticity. Guide to the comprehensive treatment of spasticity. [Article in Spanish]. Rev Neurol 2007;45(6):365–75.
- Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev Pharmacoecon Outcomes Res 2011;11(2):205–13.
- Ares B, Prieto JM, Lema M, Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler 2007;13(2):262–4.
- Confavreux C. The natural history of multiple sclerosis. In: Compston A, , eds. McAlpine's multiple sclerosis. 4th ed. Oxford: Churchill Livingstone/Elsevier; 2005: 199.
- Orton SM, Herrera BM, Yee IM, et al; for Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5(11):932–6.
- Pugliatti M, Rosati G, Carton H, The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13(7):700–22.
- Khan F, Amatya B, Turner-Stokes L. Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. Neurol Res Int 2011;2011:740505.
- Antel J, Antel S, Caramanos Z, Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012;123(5):627–38.
- Otero S, Batlle J, Bonaventura I, et al; for Grupo de Trabajo del Registro de Esclerosis Múltiple de Cataluña. Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia. [Article in Spanish]. Rev Neurol 2010;50(10):623–33.
- Modrego Pardo PJ, Latorre MA, López A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997;244(3):182–5.
- Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 2012;12(4 Suppl):3–8.